Samsara BioCapital
Latest statistics and disclosures from Samsara BioCapital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are SRRK, MLYS, ALMS, SEPN, KLRS, and represent 76.60% of Samsara BioCapital's stock portfolio.
- Added to shares of these 5 stocks: Spyglass Pharma (+$55M), STRO (+$21M), ALMS (+$13M), AgomAb Therapeutics NV (+$6.3M), CHRS (+$5.8M).
- Started 3 new stock positions in AgomAb Therapeutics NV, CHRS, Spyglass Pharma.
- Reduced shares in these 5 stocks: PVLA (-$8.3M), ABVX, CTNM, XFOR, NUVB.WS.
- Sold out of its positions in CTNM, NUVB.WS.
- Samsara BioCapital was a net buyer of stock by $89M.
- Samsara BioCapital has $1.0B in assets under management (AUM), dropping by 6.17%.
- Central Index Key (CIK): 0001744967
Tip: Access up to 7 years of quarterly data
Positions held by Samsara BioCapital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Samsara BioCapital
Samsara BioCapital holds 22 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Scholar Rock Hldg Corp (SRRK) | 32.9 | $339M | 6.9M | 49.16 |
|
|
| Mineralys Therapeutics (MLYS) | 15.5 | $159M | 5.9M | 27.09 |
|
|
| Alumis (ALMS) | 13.6 | $140M | +10% | 6.3M | 22.03 |
|
| Septerna (SEPN) | 7.4 | $76M | 3.1M | 24.03 |
|
|
| Kalaris Therapeutics (KLRS) | 7.3 | $75M | 13M | 5.77 |
|
|
| Spyglass Pharma Com Shs | 5.3 | $55M | NEW | 2.1M | 25.91 |
|
| Neurogene (NGNE) | 3.4 | $35M | 1.7M | 20.16 |
|
|
| Inventiva Sa Ads (IVA) | 2.8 | $29M | 5.2M | 5.55 |
|
|
| Sutro Biopharma Com Shs (STRO) | 2.6 | $27M | +419% | 1.1M | 24.91 |
|
| Jade Biosciences Com New (JBIO) | 1.3 | $14M | 969k | 14.05 |
|
|
| Vtv Therapeutics Cl A New (VTVT) | 1.2 | $12M | 299k | 39.66 |
|
|
| Aquestive Therapeutics (AQST) | 1.0 | $10M | 2.5M | 4.15 |
|
|
| X4 Pharmaceuticals Com New (XFOR) | 0.7 | $7.6M | -6% | 1.8M | 4.13 |
|
| Nkarta (NKTX) | 0.7 | $7.4M | 3.5M | 2.11 |
|
|
| Arcellx Common Stock (ACLX) | 0.7 | $7.0M | 61k | 114.82 |
|
|
| Upstream Bio (UPB) | 0.6 | $6.6M | 736k | 9.00 |
|
|
| Abivax Sa Sponsored Ads (ABVX) | 0.6 | $6.3M | -25% | 57k | 111.35 |
|
| Agomab Therapeutics Nv Sponsored Ads | 0.6 | $6.3M | NEW | 600k | 10.49 |
|
| Rani Therapeutics Hldgs Com Cl A (RANI) | 0.6 | $6.2M | 8.5M | 0.73 |
|
|
| Coherus Biosciences (CHRS) | 0.6 | $5.8M | NEW | 3.4M | 1.69 |
|
| Palvella Therapeutics Inc Ne (PVLA) | 0.5 | $4.8M | -63% | 38k | 124.65 |
|
| Gossamer Bio (GOSS) | 0.2 | $2.4M | 7.2M | 0.33 |
|
Past Filings by Samsara BioCapital
SEC 13F filings are viewable for Samsara BioCapital going back to 2018
- Samsara BioCapital 2026 Q1 filed May 15, 2026
- Samsara BioCapital 2025 Q4 filed Feb. 17, 2026
- Samsara BioCapital 2025 Q3 filed Nov. 14, 2025
- Samsara BioCapital 2025 Q2 filed Aug. 14, 2025
- Samsara BioCapital 2025 Q1 filed May 15, 2025
- Samsara BioCapital 2024 Q4 filed Feb. 14, 2025
- Samsara BioCapital 2024 Q3 filed Nov. 14, 2024
- Samsara BioCapital 2024 Q2 filed Aug. 14, 2024
- Samsara BioCapital 2024 Q1 filed May 15, 2024
- Samsara BioCapital 2023 Q4 filed Feb. 14, 2024
- Samsara BioCapital 2023 Q3 filed Nov. 14, 2023
- Samsara BioCapital 2023 Q1 restated filed Aug. 14, 2023
- Samsara BioCapital 2023 Q2 filed Aug. 14, 2023
- Samsara BioCapital 2023 Q1 filed May 15, 2023
- Samsara BioCapital 2022 Q4 amended filed Feb. 15, 2023
- Samsara BioCapital 2022 Q4 filed Feb. 14, 2023